Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

PURPOSE: Treatment of advanced non–small-cell lung cancer with immune checkpoint inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of patients. Clinically available tools to optimize use of ICIs and understand the molecular determinants of response are needed....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Rizvi, Hira, Sanchez-Vega, Francisco, La, Konnor, Chatila, Walid, Jonsson, Philip, Halpenny, Darragh, Plodkowski, Andrew, Long, Niamh, Sauter, Jennifer L., Rekhtman, Natasha, Hollmann, Travis, Schalper, Kurt A., Gainor, Justin F., Shen, Ronglai, Ni, Ai, Arbour, Kathryn C., Merghoub, Taha, Wolchok, Jedd, Snyder, Alexandra, Chaft, Jamie E., Kris, Mark G., Rudin, Charles M., Socci, Nicholas D., Berger, Michael F., Taylor, Barry S., Zehir, Ahmet, Solit, David B., Arcila, Maria E., Ladanyi, Marc, Riely, Gregory J., Schultz, Nikolaus, Hellmann, Matthew D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6075848/
https://ncbi.nlm.nih.gov/pubmed/29337640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.75.3384
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados